Document Detail

Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats.
MedLine Citation:
PMID:  15215655     Owner:  NLM     Status:  MEDLINE    
The effects of orally administered dipeptidyl peptidase IV (DPP-IV) inhibitor on the glucose-lowering effect of glibenclamide are still unknown. We evaluated the effects of combination treatment with a long-lasting DPP-IV inhibitor, K579 ((S)-1-[4-methyl-1-(2-pyrimidinyl)-4-piperidylamino]acetyl-2-pyrrolidinecarbonitrile), and glibenclamide on the glycemic responses to glucose loading in rats. Treatment with K579 inhibited the plasma DPP-IV activity even 8 h after the administration. K579 significantly suppressed the blood glucose elevation in glibenclamide-pretreated rats without excessive hypoglycemia. These profiles of K579 indicate that it could be useful agent to correct the postprandial glucose excursion in type 2 diabetes patients by combination treatment with glibenclamide.
Kotaro Takasaki; Takao Nakajima; Kimihisa Ueno; Yuji Nomoto; Katsuya Higo
Related Documents :
8590785 - Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glu...
2647605 - Glucose dependent insulinotropic polypeptide (gip) infused intravenously is insulinotro...
18987435 - Low, but physiological, concentration of glp-1 stimulates insulin secretion independent...
18755155 - Dpp4 inhibitors for diabetes--what next?
25491105 - Leuprolide acetate-stimulated androgen response during female puberty.
19092165 - Protection from clinical peripheral sensory neuropathy in alström syndrome in contrast ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of pharmacological sciences     Volume:  95     ISSN:  1347-8613     ISO Abbreviation:  J. Pharmacol. Sci.     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-06-24     Completed Date:  2005-01-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101167001     Medline TA:  J Pharmacol Sci     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  291-3     Citation Subset:  IM    
Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD26 / metabolism*
Blood Glucose / metabolism*
Glyburide / pharmacology
Hypoglycemic Agents / pharmacology*
Protease Inhibitors / pharmacology*
Rats, Wistar
Sulfonylurea Compounds / pharmacology*
Reg. No./Substance:
0/Blood Glucose; 0/Hypoglycemic Agents; 0/Protease Inhibitors; 0/Sulfonylurea Compounds; 10238-21-8/Glyburide; EC, CD26

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhancement of sphingosine 1-phosphate-induced phospholipase C activation during G(0)-G(1) transitio...
Next Document:  Polysaccharide extract isolated from ganoderma lucidum protects rat cerebral cortical neurons from h...